Tower Research Capital (TRC)’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-3,285
| Closed | -$13K | – | 7034 |
|
|
2022
Q1 | $13K | Sell |
3,285
-566
| -15% | -$2.05K | ﹤0.01% | 4029 |
|
|
2021
Q4 | $14K | Sell |
3,851
-29,844
| -89% | -$104K | ﹤0.01% | 4139 |
|
|
2021
Q3 | $122K | Buy |
33,695
+27,972
| +489% | +$113K | ﹤0.01% | 2225 |
|
|
2021
Q2 | $25K | Sell |
5,723
-12,982
| -69% | -$52.9K | ﹤0.01% | 3709 |
|
|
2021
Q1 | $77K | Sell |
18,705
-5,975
| -24% | -$25.9K | ﹤0.01% | 2791 |
|
|
2020
Q4 | $98K | Sell |
24,680
-162,131
| -87% | -$525K | ﹤0.01% | 2377 |
|
|
2020
Q3 | $505K | Buy |
186,811
+151,672
| +432% | +$420K | 0.01% | 1677 |
|
|
2020
Q2 | $97K | Buy |
+35,139
| New | +$98K | ﹤0.01% | 2488 |
|
|
2020
Q1 | – | Sell |
-100
| Closed | – | – | 4257 |
|
|
2019
Q4 | $0 | Sell |
100
-1,109
| -92% | -$4.54K | ﹤0.01% | 4687 |
|
|
2019
Q3 | $4K | Buy |
+1,209
| New | +$3.98K | ﹤0.01% | 3491 |
|
|
2019
Q1 | – | Sell |
-1,706
| Closed | -$5K | – | 4521 |
|
|
2018
Q4 | $5K | Sell |
1,706
-11,098
| -87% | -$36.6K | ﹤0.01% | 2966 |
|
|
2018
Q3 | $43K | Buy |
+12,804
| New | +$39.5K | ﹤0.01% | 1857 |
|
|
2018
Q2 | – | Sell |
-832
| Closed | -$2K | – | 4244 |
|
|
2018
Q1 | $2K | Sell |
832
-3,584
| -81% | -$8.07K | ﹤0.01% | 2999 |
|
|
2017
Q4 | $9K | Sell |
4,416
-13,578
| -75% | -$29.6K | ﹤0.01% | 2642 |
|
|
2017
Q3 | $59K | Buy |
+17,994
| New | +$55.5K | ﹤0.01% | 1824 |
|
|
2017
Q2 | – | Sell |
-21,373
| Closed | -$60K | – | 3693 |
|
|
2017
Q1 | $60K | Sell |
21,373
-721
| -3% | -$1.73K | 0.01% | 664 |
|
|
2016
Q4 | $51K | Buy |
22,094
+1,620
| +8% | +$3.08K | 0.01% | 1417 |
|
|
2016
Q3 | $34K | Buy |
20,474
+12,147
| +146% | +$14.9K | ﹤0.01% | 1349 |
|
|
2016
Q2 | $9K | Buy |
8,327
+8,139
| +4,329% | +$7.86K | ﹤0.01% | 2954 |
|
|
2016
Q1 | $0 | Sell |
188
-24,126
| -99% | -$23.3K | ﹤0.01% | 5205 |
|
|
2015
Q4 | $29K | Buy |
24,314
+18,607
| +326% | +$25.9K | ﹤0.01% | 925 |
|
|
2015
Q3 | $10K | Sell |
5,707
-3,605
| -39% | -$7.07K | ﹤0.01% | 2329 |
|
|
2015
Q2 | $20K | Buy |
9,312
+810
| +10% | +$1.96K | ﹤0.01% | 2113 |
|
|
2015
Q1 | $23K | Buy |
8,502
+8,300
| +4,109% | +$21.1K | ﹤0.01% | 2151 |
|
|
2014
Q4 | $1K | Sell |
202
-45,826
| -100% | -$103K | ﹤0.01% | 3775 |
|
|
2014
Q3 | $84K | Buy |
+46,028
| New | +$100K | 0.01% | 1112 |
|
|
2013
Q4 | – | Sell |
-14,293
| Closed | -$58K | – | 5050 |
|
|
2013
Q3 | $58K | Buy |
+14,293
| New | +$62.4K | 0.01% | 1784 |
|
Other funds holding ATRS
Tower Research Capital (TRC)'s ATRS Position: Q2 2022 in Review
Tower Research Capital (TRC) sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 3,285 shares — an estimated $13K sold.
Tower Research Capital (TRC) first reported a position in ATRS in Q3 2013 and held it in 27 quarters. The position peaked at $505K in Q3 2020. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Tower Research Capital (TRC) reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,285 Antares Pharma, Inc. shares in Q2 2022, an estimated $13K.
- Tower Research Capital (TRC) first reported a position in Antares Pharma, Inc. in Q3 2013 and held it in 27 quarters.
- Tower Research Capital (TRC)'s Antares Pharma, Inc. position peaked at $505K in Q3 2020.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.